PDGFRB and triple-negative breast carcinoma: Preclinical in vitro and in vivo models of triple-negative breast cancer provided further promising data regarding reduced tumor growth and metastasis in combinatorial treatment studies with the PDGFRβ-inhibiting aptamer and anti-PD-L1 antibodies [142].